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The toxicity of the cyanobacterium Microcystis aeruginosa EAWAG 127a was evaluated 
against the sensitive grazer Thamnocephalus platyurus and the extract possessed strong activity. 
To investigate the compounds responsible for cytotoxicity, a series of peptides from this 
cyanobacterium were studied using a combined genomic and molecular networking approach. The 
results led to the isolation, structure elucidation, and biological evaluation of microviridin 1777, 
which represents the most potent chymotrypsin inhibitor characterized from this family of peptides 
to date. Furthermore, the biosynthetic gene clusters of microviridin, anabaenopeptin, aeruginosin, 
and piricyclamide were located in the producing organism, and six additional natural products 
were identified by tandem mass spectrometry analyses. These results highlight the potential of 
modern techniques for the identification of natural products, demonstrate the ecological role of 
protease inhibitors produced by cyanobacteria, and raise ramifications concerning the presence of 
novel, yet uncharacterized, toxin families in cyanobacteria beyond microcystin.  
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Natural products remain an important source of biologically active compounds for drug 
discovery.1,2 The field has advanced tremendously over the recent years by exploiting innovative 
strategies such as genome-mining and molecular networking.3-5 These approaches allow for the 
identification of previously unknown structures, even in producing strains that have been 
thoroughly investigated by classical methods. Using genome-mining and networking approaches, 
gene clusters of natural products can be predicted by online tools (antiSMASH,6-9 PRISM,10 
BAGEL11-13 and RODEO14-16) and the compounds subsequently identified by the Global Natural 
Products Social Molecular Networking (GNPS) algorithm.4 The addition of other tools to the 
GNPS platform, such as VarQuest17 and DEREPLICATOR+,18 facilitate the detection of known 
natural products and the prediction of their analogues. The large and diversified database has been 
applied to the identification and discovery of natural products from various organisms,19-23 
exemplified by the isolation of the novel lipopeptides poaeamide B and bananamides 1, 2 and 3.24 
These research tools have been particularly successful in the analysis of cyanobacterial extracts25-
28 recently highlighted by the global metabolomics study of Microcystis.29  
In the context of our work on new cyanobacterial toxins,30-36 we have postulated that strong 
protease inhibitors can display biological effects beyond deterrence leading to fatal effects on 
grazers. Experimental support for this hypothesis is documented in a number of studies,37-40 
providing evidence that peptides from different classes such as cyanopeptolins and aeruginosins 
can display strong grazer toxicity.31-34,41 In order to further corroborate the production of multiple 
toxins by cyanobacteria, we were interested in potent protease inhibitors from other classes, which 
have not yet been characterized as cyanobacterial toxins. Building on these previous studies, we 
initiated a screening campaign for the identification of natural products possessing strong 
cytotoxicity using Thamnocephalus platyurus (T. platyurus) as a grazer model system. The results 
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of this investigation led to the isolation of microviridin 1777 (1), the most potent chymotrypsin 
inhibitor from its family to date.  
 
Figure 1. A) Structure of microviridin 1777 (1) and B) its peptidic sequence containing the 
highlighted post-translational modifications. 
Results and Discussion 
A preliminary screening targeted at grazer toxicity and cytotoxicity was performed evaluating 
several cyanobacterial extracts on T. platyurus. Extracts from Microcystis aeruginosa EAWAG 
127a (M. aeruginosa EAWAG 127a) were found to exhibit modest cytotoxicity against T. 
platyurus (LD50 = 0.43 mg/mL, Supporting Information, Figure S12). Building on the previously 
discussed hypothesis that potent protease inhibitors can be lethal to grazers, we decided to study 
the secondary metabolite peptides produced by M. aeruginosa EAWAG 127a. Additionally, the 
interest in this cyanobacterial strain was reinforced by its promising results from earlier 
screening.42 A combination of metagenomic and metabolite profiling was used for this study. A 
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small-scale extraction followed by UHPLC-HRMS/HRMS measurements were performed and the 
data were analyzed using the GNPS platform. Furthermore, the DNA of the organism was 
extracted following a standard protocol,43 sequenced, and the resulting data were analyzed using 
the genome-mining tools RODEO14-16 and antiSMASH.6-9 
 
To identify the peptides produced by M. aeruginosa EAWAG 127a, biosynthetic gene clusters 
of (ribosomally synthesized and post-translationally modified peptides) (RiPPs) and non-
ribosomal peptides (NRP) were identified by antiSMASH and the produced natural products were 
identified using the GNPS platform. Using this approach, the microviridin-like biosynthetic gene 
cluster was identified. This cluster bears two precursor peptides, which were confidently predicted 
by virtue of their canonical TxKxPSD motif44-47 (Figure 2 and Supporting Information, Table S5). 
The two compounds were identified as microviridin 1777 (1)48-50 and microviridin O.51,52 
Microviridins have been discovered and recognized as protease inhibitors since 1990.53 They are 
exemplified by a tricyclic scaffold and their biosynthesis has been extensively studied.46,47,50,54-56 
These compounds constitute a class of RiPP50 and the intramolecular ω-ester and ω-amide bonds 
are formed by ATP-grasp enzymes (members of InterPro families IPR026439 and 
IPR026446).46,47  
The analysis of the extract by UHPLC revealed that microviridin 1777 (1) was found as the 
major compound in the M. aeruginosa EAWAG 127a extract. As the microviridin class of 
compounds has been characterized for its serine protease inhibitory activity,44 we hypothesized 
that the compound was primarily responsible for the observed T. platyurus toxicity. We therefore 
isolated, characterized, and evaluated the biological activity purified microviridin 1777 (1). 
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Figure 2. Alignment of the microviridin B and 1777 biosynthetic gene clusters. Accession ID 
(microviridin B): AM943877.1. From left to right: (protein accession IDs) CAQ_16116.1 to 
CAQ_16120.1.44 Accession ID: (microviridin 1777): SRLN00000000. From left to right: (protein 
accession IDs): EZJ55_03500 to EZJ55_03525. mdnA, precursor peptide (red); mdnB and mdnC, 
ATP-grasp ligases (blue, purple); mdnD, N-acetyltransferase (orange); mdnE, ABC transporter 
(yellow).44 
In order to obtain a sufficient quantity of microviridin 1777 (1), a larger scale fermentation (50 
L) of M. aeruginosa EAWAG 127a was initiated. The isolation process was optimized by pre-
separation on a solid-phase extraction column using mixtures of MeOH and H2O, which 
successfully separated another compound possessing similar retention time on the UHPLC 
column. Microviridin 1777 (1) was subsequently isolated by multiple preparative HPLC runs and 
its structure was elucidated (Figure 3) by extensive NMR (Table 1) and HRMS/HRMS analyses. 
The molecular formula of the compound was calculated to be C87H111N17O24 by the detection of 
the doubly protonated molecule [M + 2H]2+ = 889.9058 Da. Based on 1H, 13C NMR (Table 1), and 
the UV spectrum (Supporting Information, Figure S2), the compound was deduced to be a peptide, 
which supported the genomic data.29 Each amino acid was identified by their typical proton and 
carbon chemical shifts and their correlation in COSY, TOCSY, HMBC and ROESY spectra.37,53,57-
60  The connectivity between the residues in the side chain was determined to be Ac-Tyr1-Asn2-
Val3 by the analysis of the key correlations on the HMBC, ROESY and TOCSY spectra. The acetyl 
group was deduced to be on the tyrosine (Tyr1) residue due to the HMBC correlation between the 
NH of the amino acid and the carbonyl of the acetyl group. Following the same strategy, the 
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connection between Tyr1 to Asn2, Asn2 to Val3, and Val3 to Thr4, was determined by the HMBC 
correlation between the NH atom of one amino acid with the carbonyl C atom of the adjacent 
residue. The amino acid sequence of the first cycle was elucidated to be Thr4-Leu5-Lys6-Tyr7-Pro8-
Ser9-Asp10 using the HMBC correlation between the NH to the C=O of the other amino acid except 
for Pro8, Ser9 and Asp10. The connectivity between Pro8 and Tyr7 was deduced with a ROESY 
correlation between the aromatic proton of Tyr7 and the α-proton of Pro8, the connectivity between 
Pro8 and Ser9 was determined by the HMBC correlation between the α-proton of Ser9 to the C=O 
of Pro8. No correlations connecting Ser9 and Asp10 were observed. The composition of the N-
terminal macrolactone was supported by the HMBC correlation between Thr4 H-3 and the γ-C=O 
of Asp10. The amino acids forming the second macrocycle were identified as Trp11 and Glu12 by 
the HMBC correlation between the NH of Glu12 to the C=O of Trp11 and the ester bond between 
Glu12 and Ser9 was determined by the HMBC correlation of the β-proton of Ser9 with the C=O of 
the Glu12 at the δ position. The last residue of the sequence was deduced to be Glu13 and Phe14 by 
comparison of the structure with other known microviridins. Finally, composition of the 
macrolactam was identified by the HMBC correlation between the ε-NH of Lys6 and the C=O of 
the δ position of Glu13. 
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Figure 3. Structure of microviridin 1777 (1) isolated from M. aeruginosa EAWAG 127a with 
key HMBC (blue) and ROESY (red) correlations highlighted. 
Table 1. NMR Data Analysis of Microviridin 1777 (1). 
AA pos. δC, type δH (J in Hz) HMBCa 
Ac 1 169.1, C   
 2 22.3, CH3 1.75, s Ac(1) 
Tyr1 1 171.6, C   
 2 54.3, CH 4.43, mbb Tyr1(1), Tyr1(3), Tyr1(4), Ac(1) 
 3 36.7 CH2 2.89, m Tyr1(2), Tyr1(4), Tyr1(5,9) 
   2.61, m Tyr1(2), Tyr1(4), Tyr1(5,9) 
 4 127.9, C   
 5,9    
b 
129.9, CH 7.02, m Tyr1(3), Tyr1(4), Tyr1(6,8), Tyr1(9) 
 9 
 6,8 114.8, CH 6.63, m Tyr1(9) 
 7 155.7, C   
 OH  9.18, s  
 NH  8.03, d (8.2) Ac(1), Tyr1(3), Tyr1(3) 
Asn2 1 170.6, C   
 2 49.7, CH 4.61, m Asn2(1), Asn2(3), Asn2(4) 
 3 36.6, CH2 2.46, m Asn2(1), Asn2(3), Asn2(4) 
   2.59, m Asn2(1), Asn2(3), Asn2(4) 
 4 171.5, C   
 NH  8.38, d (7.7) Tyr1(1), Asn2(2), Asn2(3) 
 NH2  6.89, m  Asn2(3), Asn2(4) 
Val3 1 171.0, C   
 2     b 57.1, CH 4.40, mb Val3(1), Val3(3), Val3(4), Val3(4'), 
Asn2(1) 
 3        
b 
30.6, CH 2.01, mb Val3(1), Val3(2), Val3(4), Val3(4') 
 4 18.9, CH3 0.84, d (6.8) Val3(2), Val3(3), Val3(4') 
 4' 17.4, CH3 0.80, d (6.8) Val3(2), Val3(3), Val3(4) 
 NH  7.53, d (8.9) Asn2(1), Val3(2) 
Thr4 1 168.7, C   
 2 54.6, CH 4.57, m Thr4(1), Thr4(3) 
 3 70.8, CH 5.33, m Val3(1), Thr4(2), Thr4(4), Asp10(4) 
 4 16.8, CH3 1.15, d (6.4) Thr4(2), Thr4(3) 
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 NH  7.70, d (8.8) Val3(1) 
Leu5 1 170.2, C   
 2 50.7, CH 4.23, m Leu5(1), Leu5(3) 
 3 40.2, CH2 1.37, m Leu5(2), Leu5(4), Leu5(5), Leu5(5') 
   1.56, m Leu5(2), Leu5(4), Leu5(5), Leu5(5') 
 4 23.9, CH 1.45, m Leu5(3), Leu5(5), Leu5(5'), 
 5 21.3, CH3 0.74, d (6.4) Leu5(3), Leu5(4), Leu5(5') 
 5' 23.1, CH3 0.82, d (6.6) Leu5(3), Leu5(4), Leu5(5) 
 NH  8.27, d (8.6) Thr4(1), Leu5(2) 
Lys6 1 170.1, C   
 2 52.5, CH 4.12, m Lys6(1), Lys6(3), Lys6(4) 
 3 32.1, CH2 1.53, m Lys6(2), Lys6(4) 
 4 21.6, CH2 1.22, m Lys6(3), Lys6(5), Lys6(6) 
 5 28.7, CH2 1.44, m Lys6(3), Lys6(4), Lys6(6) 
   1.29, m Lys6(3), Lys6(4), Lys6(6) 
 6 37.7, CH2 2.94, m Lys6(5), Lys6(6) 
   3.14, m Lys6(5), Lys6(6) 
 αNH 6.70, d (7.4) Leu5(1) 
 εNH  6.91, m Lys6(6), Glu13(5) 
Tyr7 1 170.9, C   
 2          
n 
51.6, CHn 4.36, mn Tyr7(1), Tyr7(3), Tyr7(4), Lys6(1) 
 3  37.4, CH2 2.77, mn Tyr7(1), Tyr7(2), Tyr7(4), Tyr7(5,9) 
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   2.67, mn Tyr7(1), Tyr7(2), Tyr7(4), Tyr7(5,9) 
 4 126.3, C   
 5,9  130.0, CH 6.95, mn Tyr7(3), Tyr7(4), Tyr7(6,8) Tyr7(7) 
 6,8 115.1, CH 6.67, m Tyr7(4), Tyr7(5,9) Tyr7(7) 
 7 156.2, C   
 OH  9.34, s  
 NH  8.33, d (8.3) Lys6(1), Tyr7(2) 
Pro8 1 170.7, C   
 2 60.4, CH 3.47, m Pro8(1), Pro8(3) 
 3 30.7, CH2 1.62, m  
   1.53, m  
 4 31.8, CH2 1.92, m  
   2.09, m  
 5 46.0, CH2 3.41, m  
   3.23, m  
Ser9 1 169.0, C   
 2 52.1, CH 4.47, m Pro8(1) 
 3 61.8, CH2 4.20, m Ser9(1) 
   4.54, m Glu12(5) 
 NH  7.36, s Asp10(1) 
Asp10 1 171.5, C   
 2 54.1, CH 4.42, m Asp10(4) 
 3 34.5, CH2 2.63, m Asp10(1), Asp10(4) 
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   2.77, m  
 4 169.4, C   
 NH  n.o.  
Trp11 1 171.1, C   
 2 53.4, CH 4.58, m Trp11(1) 
 3 25.8, CH2 3.18, m  
   3.28, m Trp11(1) 
 1' NH  10.86, s Trp11(2'), Trp11(3'), Trp11(8'), Trp11(9') 
 2' 123.3, CH 7.19, m Trp11(3'), Trp11(8'), Trp11(9') 
 3' 109.4, C   
 4' 118.0, CH 7.47, d (7.8) Trp11(3'), Trp11(5'), Trp11(8'), Trp11(9') 
 5'    121.0, CH 7.05, m Trp11(4'), Trp11(6'), Trp11(7'), Trp11(8'), 
Trp11(9') 
 6'  118.4, CH 6.97, m Trp11(4'), Trp11(5'), Trp11(7'), Trp11(8'), 
Trp11(9') 
 7' 111.4, CH 7.28, m Trp11(6'), Trp11(8') 
 8' 127.2, C   
 9' 136.1, C   
 αNH  n.o.  
Glu12 1 n.o.   
 2 52.5, CH 4.16, m  
 3 24.4, CH2 1.61, m  
   1.85, m  
 13 
 4 29.4, CH2 1.33, m  
   2.08, m  
 5 171.0, C   
 NH  6.50, d (8.3)  
Glu13 1 169.7, C   
 2 52.4, CH 4.03, m  
 3 27.9, CH2 2.08, m  
   1.53, m  
 4 31.8, CH2 1.91, m Glu13(5) 
 5 171.0, C   
 NH  7.41, m  
Phe14 1 172.7, C   
 2 55.2, CH 4.02, m  
 3  37.4, CH2 3.07, dd 
(13.5, 5.2) 
Phe14(1), Phe14(2), Phe14(4), Phe14 (5,9) 
   2.91, m Phe14(2), Phe14(4), Phe14(5,9), 
Phe14(6,8) 
 4 139.1, C   
 5,9 129.5, CH 7.16, m Phe14(3), Phe14(4), Phe14(6,8), Phe14(7) 
 6,8 127.5, CH 7.17, m Phe14(4), Phe14(5,9), Phe14(7) 
 7 125.4, CH 7.10, m Phe14(5,9), Phe14(6,8) 
 NH  7.29, m  
 14 
aHMBC correlations are given from proton(s) stated to the indicated carbon atom. Abbreviation: 
n.o. for not observed. 
 
Having the characterized and purified natural product in hand, we next investigated biological 
activity. The potency of microviridin 1777 (1) was evaluated against T. platyurus, which resulted 
in an LD50 value of 95 µM. The cytotoxicity of purified 1 was around five times greater than the 
extract, but remains roughly one order of magnitude weaker than other cyanobacterial toxins.27-37 
To understand the mechanism of action of microviridin 1777 (1), an enzyme assay with trypsin, 
chymotrypsin, and elastase was performed (Figure 4) using modified literature procedures.31,45 
Whereas only weak inhibition of trypsin could be observed (IC50 > 10 µM), microviridin 1777 (1) 
displayed stronger activity against elastase with an IC50 of 160 (± 10) nM. This is in line with data 
for other microviridins in the literature, where peptides carrying either leucine or valine at position 
5 result in good activity against elastase.50 Inhibitor 1 demonstrated more potent activity against 
chymotrypsin with an IC50 value of 100 (± 10) nM, which to date represents the most potent 
chymotrypsin inhibitory activity of any microviridin (Supporting Information Table S4). 
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Figure 4. Fractional activity of 1 on the chymotrypsin, trypsin, and elastase protease inhibition 
assay (n=3).  
A detailed analysis of the extracts by UHPLC-HRMS/HRMS revealed the presence of 
microviridin M (2),51 an N-terminally truncated version of microviridin 1777 (1) (Figure 1). This 
compound was produced heterologously from E. coli and its IC50 value against chymotrypsin and 
trypsin were higher than 34 µM, and an IC50 value of 2.9 µM was determined against elastase.51 
This result highlights the importance of the microviridin 1777 (1) side chain for its serine protease 
activity. Additionally, microviridin O was not identified in the extract although the precursor 
peptide was found in the genome (EZJ55_03525). 
  
Using the genomic approach, the NPRS gene cluster of the anabaenopeptin family of natural 
products was identified in the genome of M. aeruginosa EAWAG 127a using antiSMASH 
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(Figure 5). The cyclic peptides were expected to contain eight amino acids due to the presence of 
eight predicted adenylation domains. The organization of the cluster was in agreement with those 
previously isolated from M. aeruginosa61,62 and in Planktothrix agardhii.63 The UHPLC-
HRMS/HRMS data were analyzed with the GNPS platform using the DEREPLICATOR+ 
algorithm and three known anabaenopeptins (A, B and F) and oscillamide Y64 were detected. The 
identities of the compounds was confirmed by their characteristic HRMS/HRMS pattern 
(Supporting Information, Figures S7-S10).65 The molecular networking analysis distinguished two 
classes of anabaenopeptins which possessed either a tyrosine or arginine. 
Continuing our genomic investigation, we localized the aeruginosin NRPS gene cluster using 
antiSMASH (Figure 5). As observed in previous analysis of M. aeruginosa,61 the gene responsible 
for the production of the halogenase (aerJ) was not identified in the genome of the EAWAG 127a 
strain. Analysis of the extract by UHPLC-HRMS/HRMS data led to the identification of 
aeruginosin 102 derivative 3 missing the sulfate group (Figure 6).66,67 The identity of the natural 
product was corroborated by tandem MS (Supporting Information, Figure S11). 
Finally, the biosynthetic gene cluster responsible for the production of piricyclamide was 
predicted by antiSMASH with a similarity percentage of more than 60% to a reported gene cluster 
from this family. Interestingly, the putative piricyclamide gene cluster in M. aeruginosa EAWAG 
127a does not possess the geranyltransferase pirF (Figure 5).70 These modified cyclic peptides 




Figure 5. Alignment of anabaenopeptin gene cluster from Planktothrix agardhii NIVA-CYA 
126/8 (accession ID: EF672686.1, from left to right: WP_042156037.1 to WP_042156027.1)63 
and the one of M. aeruginosa EAWAG 127a (accession ID: SRLN00000000, from left to right: 
EZJ55_13000 to EZJ55_13035). Alignment of aeruginosin gene cluster from Microcystis 
aeruginosa PCC 7806 (accession ID: AM778955.1, from left to right: CAO90437.1 to 
CAO90422.1)68,69 and the one of M. aeruginosa EAWAG_127a (accession ID: SRLN00000000, 
from left to right: EZJ55_15670 to EZJ55_15725). Alignment of piricyclamide gene cluster from 
M. aeruginosa PCC 7005 (accession ID: JQ951924.1, from left to right: AFK79987.1 to 
AFK79998.1)71 and the one of M. aeruginosa EAWAG 127a (accession ID: SRLN00000000, from 
left to right: EZJ55_18570 to EZJ55_18645). 
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Figure 6. Structure and configurations of microviridin M (2) and aeruginosin 102 derivative 3 
missing the sulfate group at the phenol position of the p-hydroxyphenyllactic acid residue 
In conclusion, M. aeruginosa EAWAG 127a was selected as a promising producer of protease 
inhibitors during a preliminary screening against T. platyurus. To identify putative toxins produced 
by this strain, the secondary metabolite peptides were studied using a metabologenomic approach. 
The DNA of the cyanobacterium was isolated, sequenced, and analyzed using freely available 
online tools. Additionally, the extract was obtained, analyzed with UHPLC HRMS/HRMS, and 
the resulting data were uploaded on the GNPS platform. The combined strategy led to the 
identification and structure elucidation of microviridin 1777 (1), the most potent chymotrypsin 
inhibitor from the microviridin family. Additionally, inhibitor 1 was found to possess an IC50 value 
of 95 µM against T. platyurus, which reinforces the ecological importance of cyclic peptides 
produced by cyanobacteria. Furthermore, anabaenopeptins A, B and F, oscillamide Y, the 
aeruginosin 102 derivative 3, and a truncated version of microviridin 1777 (1), microviridin M (2), 
were identified in the extract using the GNPS platform. These results highlight the efficacy and 
robustness of database mining tools. Finally, assessment of freshwater quality should include other 
compound classes beyond microcystin. 
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Experimental Section 
General Experimental Procedures. All 1H and 13C NMR spectra were recorded using a Bruker 
Avance 600 MHz (1H) and 151 MHz (13C) spectrometer at RT and 310 K. Chemical shifts (δ-
values) are reported in ppm, spectra were calibrated relative to the residual proton chemical shifts 
(DMSO-d6, δ = 2.50) and the residual carbon chemical shifts (DMSO-d6, δ = 39.52) of the solvents, 
multiplicity is reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet or 
unresolved and coupling constant J in Hz. The Mass Spectrometry Service of the University of 
Zurich recorded the HRMS-ESI and MS/MS spectra on a QExactive instrument (Thermo Fisher 
Scientific, Bremen, Germany) equipped with BEH C18 1.7 µM 2.1 × 150 mm column, a heated 
electrospray (ESI) ionization source and connected to a Dionex Ultimate 3000 UHPLC system. 
Preparative HPLC was carried out on a Shimadzu HPLC system equipped with a Gemini column 
(5 µm, NX-C18 110Å, 250 × 21.2 mm) and fraction collector. Fraction analysis was conducted on 
a Thermo Fisher Scientific Ultimate 3000 LC instrument coupled to a triple quadrupole Quantum 
Ultra EMR MS (H-ESI II ion source) equipped with a reversed-phase column (Kinetex® EVO C18, 
1.7 µm, 100 Å, 50 × 2.1 mm Phenomenex). The solvents were purchased from Sigma-Aldrich, 
Acros or Fluka in HPLC grade. Removing the solvent under reduced pressure was carried out with 
a rotary evaporator with a water bath temperature of 40 °C. A Synergy H1 microplate reader from 
BioTek was used to record fluorescence and absorbance of the enzyme assays. The enzymes 
trypsin type I from bovine pancreas, α-chymotrypsin II from bovine pancreas and elastase 
pancreatic type I from porcine as well as the substrate SucALA3-pNA were purchased from Sigma 
Aldrich. The substrates Glutaryl-Gly-Arg-AMC and Glutaryl-Gly-Gly-Phe-AMC were purchased 
from Bachem AG. Cryst Freeze dryer ALPHA 1-4 LD plus from Kuhner AG was used to perform 
lyophilization.  
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Sources and Cultivation of Cyanobacteria. The strain M. aeruginosa EAWAG 127a is part of 
the cyanobacteria collection of the University of Zurich, formerly located at EAWAG (Swiss 
Federal Institute of Aquatic Science and Technology). The strain was grown in a 60 L batch reactor 
(Z medium) with a light/dark cycle of 12:12 h and continuous airflow. The biomass was obtained 
by centrifugation (4500 × g, 30 min, 4 °C) of 1 L of the culture and removing the medium by 
filtration.  
Extraction and Isolation. The wet biomass (10.22 g) was extracted with an aq. MeOH soln. 
(60%, 150 mL), and the resulting mixture was sonicated (3 × 3 min with 5 min breaks, to avoid 
overheating), harvested by centrifugation (9000 × g, 30 min, 4 °C) and the soln. was carefully 
decanted. This extraction procedure was repeated once. The extracted MeOH solutions were 
combined, evaporated under reduced pressure and the residue was lyophilized. The dry crude 
material (251.9 mg) was dissolved in an aq. MeOH soln. (40%), transferred in a Falcon tube, 
harvested by centrifugation (9000 × g, 10 min, 4 °C). The mixture was loaded on a C18 solid-phase 
extraction (SPE) column (Supelco Discovery DSC-18, 2 g, that was pre-washed with MeOH and 
H2O and conditioned with 40% aq. MeOH soln.). The loaded column was rinsed with aq. MeOH 
soln. (40%) followed by extensive elution with aq. MeOH soln. (60%). The remaining solid in the 
Falcon tube was dissolved in MeOH (60%), harvested by centrifugation (9000 × g, 10 min, 4 °C) 
and also loaded on the C18 SPE column and the compounds were eluted with aq. MeOH soln 
(60%). After this pre-separation, the 60% MeOH fractions were combined and the MeOH was 
removed under reduced pressure and the mixture was lyophilized. The greenish powder was 
resolubilized in MeOH (60%), filtered through a HPLC filter and the compound was isolated by 
preparative HPLC (Gemini, 5 µm, NX-C18 110 Å, 250 × 21.2 mm, 20 mL/min). The MeCN/H2O 
gradient started with 5% to 40% in 5 min, then from 40% to 41.7% in 12 min and finally from 
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41.7% to 100% in 1 min. The column was re-equilibrated for 5 min to the initial gradient of 5%. 
Microviridin 1777 (1, 11.42 min) was isolated as a colorless solid (0.84 mg/L). Oscillamide Y 
(11.78 min) was isolated as a colorless solid (0.45 mg/L). 
Microviridin (1): colorless solid; 1H NMR (600 MHz, DMSO-d6) δ 10.86 (s, 1H), 9.34 (s, 1H), 
9.18 (s, 1H), 8.38 (d, J = 7.7 Hz, 1H), 8.33 (d, J = 8.3 Hz, 1H), 8.27 (d, J = 8.6 Hz, 1H), 8.03 (d, 
J = 8.2 Hz, 1H), 7.70 (d, J = 8.8 Hz, 1H), 7.53 (d, J = 8.9 Hz, 1H), 7.47 (d, J = 7.8 Hz, 1H), 7.42 
– 7.38 (m, 1H), 7.36 (s, 1H), 7.29 – 7.27 (m, 2H), 7.21 – 7.13 (m, 5H), 7.13 – 7.07 (m, 1H), 7.07 
– 7.00 (m, 3H), 6.99 – 6.92 (m, 3H), 6.92 – 6.85 (m, 2H), 6.70 (d, J = 7.4 Hz, 1H), 6.69 – 6.65 (m, 
3H), 6.66 – 6.61 (m, 2H), 6.50 (d, J = 8.3 Hz, 1H), 5.37 – 5.30 (m, 1H), 4.63 – 4.52 (m, 4H), 4.50 
– 4.45 (m, 1H), 4.45 – 4.32 (m, 4H), 4.26 – 4.18 (m, 2H), 4.18 – 4.09 (m, 2H), 4.07 – 3.98 (m, 
2H), 3.50 – 3.45 (m, 1H), 3.43 – 3.38 (m, 1H), 3.28 – 3.21 (m, 2H) 3.21 – 3.11 (m, 2H), 3.07 (dd, 
J = 13.5, 5.2 Hz, 1H), 2.96 – 2.86 (m, 3H), 2.81 – 2.71 (m, 2H), 2.70 – 2.56 (m, 4H), 2.53 – 2.44 
(m, 2H), 2.12 – 1.99 (m, 4H), 1.95 – 1.87 (m, 1H), 1.86 – 1.82 (m, 1H), 1.75 (s, 3H), 1.67 – 1.58 
(m, 3H), 1.58 – 1.49 (m, 3H), 1.48 – 1.40 (m, 2H), 1.40 – 1.27 (m, 3H), 1.26 – 1.19 (m, 2H), 1.15 
(d, J = 6.4 Hz, 3H), 0.85 – 0.84 (m, 3H), 0.84 (d, J = 6.8 Hz, 3H), 0.82 (d, J = 6.6 Hz, 3H), 0.80 
(d, J = 6.8 Hz, 3H), 0.75 (d, J = 6.4 Hz, 3H); 13C NMR (151 MHz, DMSO-d6) δ 172.75, 171.63, 
171.55, 171.53, 171.09, 171.06, 170.98, 170.90, 170.75, 170.64, 170.23, 170.05, 169.73, 169.39, 
169.13, 168.97, 168.75, 156.19, 155.69, 139.07, 136.15, 129.96, 129.87, 129.48, 127.95, 127.50, 
127.15, 126.31, 125.43, 123.36, 120.99, 118.39, 118.02, 115.07, 114.78, 111.43, 109.43, 70.83, 
61.80, 60.44, 57.05, 55.19, 54.60, 54.27, 54.11, 53.37, 52.47, 52.43, 52.35, 52.07, 51.55, 50.70, 
49.71, 46.03, 40.18, 37.66, 37.36, 36.66, 36.64, 34.54, 32.11, 31.82, 30.68, 30.65, 29.43, 28.65, 
27.92, 25.75, 24.38, 23.87, 23.10, 22.32, 21.60, 21.25, 18.93, 17.40, 16.81; HRESI m/z 889.9058 
Da [M + 2H]2+ (calc. for C87H113N17O24 889.9067 Da). 
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Mass spectrometry and molecular networking analysis. The wet biomass (4.71 g) was 
extracted with an aq. MeOH soln. (60%, 150 mL), and the resulting mixture was sonicated (3 × 3 
min with 5 min breaks to avoid overheating), harvested by centrifugation (9000 × g, 30 min, 4 °C) 
and the mixture was carefully decanted. This extraction procedure was repeated once. The MeOH 
solutions were combined, evaporated under reduced pressure, and the residue was lyophilized. The 
dry crude material (66 mg) was dissolved in aq. MeOH soln. (80%) with a concentration of 
8 mg/mL. The solutions were harvested by centrifugation in Eppendorf tubes. UHPLC-DAD-
HRMS/HRMS spectra were measured in positive mode on a BEH C18 2 × 150 mm, with a 
normalized collision energy (NCE) of 15, 22 and 30. The MeCN/H2O gradient varied from 3% to 
100% in 12 min and the column was washed for 3 min. The column was recalibrated in 2 min to 
the initial gradient of 3%. The UHPLC-HRMS/HRMS data were uploaded on the GNPS database4 
and the analyses were performed with the DEREPLICATOR and DEREPLICATOR+ for the 
dereplication process. A molecular network was created using the online workflow at GNPS. The 
data was filtered by removing all MS/MS peaks within +/- 17 Da of the precursor m/z. MS/MS 
spectra were window filtered by choosing only the top 6 peaks in the +/- 50 Da window throughout 
the spectrum. The data was then clustered with MS-Cluster with a parent mass tolerance of 1.0 Da 
and a MS/MS fragment ion tolerance of 0.5 Da to create consensus spectra. Further, consensus 
spectra that contained less than two spectra were discarded. A network was then created where 
edges were filtered to have a cosine score above 0.6 and more than 6 matched peaks. Further edges 
between two nodes were kept in the network if and only if each of the nodes appeared in each 
other's respective top 10 most similar nodes. The spectra in the network were then searched against 
GNPS spectral libraries. The library spectra were filtered in the same manner as the input data. All 
matches kept between network spectra and library spectra were required to have a score above 0.7 
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and at least 6 matched peaks. Analog search was enabled against the library with a maximum mass 
shift of 100.0 Da. 
Trypsin and chymotrypsin assay. The trypsin and chymotrypsin inhibition assays were carried 
out using the procedure from Gademann et al.31 The fluorescence measurements were carried out 
using a fluorescence microplate reader set at λex = 355 nm and λem = 480 nm and measuring the 
kinetic data points every 30 s for 1 h in a 96 dark well plate. Trypsin and chymotrypsin were 
dissolved in a Tris-HCl buffer (50 mM, pH = 7.5) containing NaCl (100 mM), MgCl2 (10 mM), 
CaCl2 (1 mM), BSA (0.1%) Triton X-100 (0.01%). To ensure the solubility of the substrate, 
DMSO (7.5%) was added to the buffer and this buffer was also used as the blank. The final protease 
and substrate concentrations are listed in a table reported in the supporting information (Table S1). 
The final inhibitor concentrations ranged between 0.1 and 10 nM. The inhibition assay was carried 
out by incubation of protease solution (50 µL) with microviridin 1777 (1) solution (50 µL) for 
30 min at RT. After addition of the substrate solution (50 µL) using a multichannel pipette 
dispenser, the data were immediately collected on the microplate reader. The control experiment 
was performed by the incubation of blank buffer (50 µL) and the enzyme solution (50 µL) for 30 
min following by the addition of the substrate solution (50 µL). The inhibition curves and the 50% 
inhibition values (IC50) were calculated using the linear regression of the substrate/enzyme rate 
respectively substrate/inhibitor rate of the first 10 min and then dividing the inhibition slope 
through the substrate slope. To determine the fractional activity and the IC50 value a nonlinear 
regression sigmoidal four-parameter curve was determined using Prism 7. 
Elastase assay. The elastase inhibition assay was carried out using a modified procedure 
recently published by Dittmann and co-workers.45 Elastase, its substrate and microviridin were 
dissolved in a Tris-HCl buffer (50 mM, pH = 7.5) and the enzyme and the inhibitor were incubated 
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for 30 min at RT. After the substrate addition, the absorbance was immediately collected on a 
microplate reader at 410 nm over 15 min at 37 °C. Linear regression was performed of the 
substrate/enzyme rate respectively substrate inhibitor rate on the first 5 min and then dividing the 
inhibition slope through the substrate slope. To determine the fractional activity and the IC50 value 
a nonlinear regression sigmoidal four-parameter curve was determined using Prism 7. 
Toxicity assay. The toxicity assay was conducted with Thamnotoxkit F, crustacean toxicity 
screening test for freshwater, and it was purchased from MicobioTest Inc., Kleimoer 15, 9030 
Mariakerke (Gent), Belgium. Throughout the assay the standard operational procedure was 
followed. The standard freshwater was prepared, adding the concentrated salt solutions in the given 
sequence to 800 mL of MilliQ water in a 1 L volumetric flask, followed by the addition of water 
to the 1 L mark and bubbling air with an aquarium pump for 20 min. The cyst hatching was 
performed by a 1:8 dilution of the standard freshwater with MilliQ water (2.5 mL:17.5 mL) to 
prepare the hatch medium. The hatch medium was added to the tube with cysts. During a 30 min 
period the tube with the cysts was shaken at regular intervals. The cysts were then transferred to a 
petri dish with 15 mL of diluted standard freshwater. The petri dish was shaken gently to equally 
distribute the cysts and then incubated for 22 h at 25 °C under a continuous illumination of 
3600 Lux. Between 10 and 20 shrimps were transferred to each of the 24 wells and the different 
concentrations of microviridin 1777 (1) and extract as well as a positive and negative control were 
performed in triplicates and the results are found in the supporting information (Tables S2 and S3). 
To the extract soln. DMSO (0.2%) was added to enhance the solubility.  
DNA isolation and sequencing. The DNA of M. aeruginosa EAWAG 127a was obtained using 
a modified protocol.43 The cyanobacterium M. aeruginosa EAWAG 127a culture (10 mL) was 
transferred into a Falcon tube, harvested by centrifugation (4,500 × g, 30 min, 4 °C) and the 
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supernatant was discarded to obtain the biomass. The biomass was transferred in an Eppendorf 
tube using the buffer T1/10 (500 µL, 10 mM, Tris-HCl, 0.1 mM EDTA-Na2, pH = 8). A mixture 
of phenol:chloroform (450 µL, 1:1 v/v), sterile glass beads (150 µL) and an aq. SDS solution 
(20 µL, 10%) were added, vortexed (1 min), cooled on ice (1 min) and this process was repeated 
three times. The mixture was centrifuged (16,100 × g, 15 min, RT) and the supernatant was 
transferred to an Eppendorf tube and the aq. solution was washed with phenol (1. eq. volume, 450 
µL), phenol:chloroform (1. eq. volume, 450 µL, 1:1 v/v, 3x) and with chloroform (1. eq. volume, 
450 µL, 3x). An aq. solution ethanol (2.5 eq. volume, 1.125 mL) and an aq. potassium acetate 
solution (0.1 eq. volume, 45 µL, 3 Μ, pH = 5.2) were added and left at –20 °C overnight to let the 
DNA precipitate. The precipitated DNA was taken out, washed with an aq. ethanol solution (70%) 
and dried under a gentle nitrogen flow.72,73 The resulting DNA was dissolved in water (100 µL) 
and the concentration was analyzed by nanodrop (438.5 ng/µL, 43.8 μg). 
Library Preparation and Sequencing. The SMRTbell library was produced using the DNA 
Template Prep Kit 1.0 (Pacific Biosciences p/n 100-259-100). The concentration of the input 
genomic DNA was measured using a Qubit Fluorometer dsDNA Broad Range assay (Life 
Technologies p/n 32850). gDNA (11 µg) were mechanically sheared to an average size distribution 
of 15-20 kb using a Covaris g-Tube (Kbiosciences p/n 520079). The resulting size distribution was 
analyzed on a Femto Pulse automated electrophoresis system (Agilent). Sheared gDNA (6 µg) was 
DNA damage- and end-repaired using polishing enzymes. A blunt end ligation reaction followed 
by exonuclease treatment was performed to create the SMRTbell template. Size-selection of the 
SMRTbell library was done on a Blue Pippin device (Sage Science) to enrich for fragments > 11 
kb. The sized-selected library was quality inspected and quantified on a Femto Pulse (Agilent) and 
on a Qubit Fluorometer (Life Technologies) respectively. A ready to sequence SMRTbell-
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Polymerase Complex was created using the P6 DNA/Polymerase binding kit 2.0 (Pacific 
Biosciences p/n 100-236-500) according to the manufacturer’s instructions. The Pacific 
Biosciences RS2 instrument was programmed to load and sequence the library on one SMRT cell 
v3.0 (Pacific Biosciences p/n100-171-800), taking a movie of 360 minutes per cell. MagBead 
loading (Pacific Biosciences p/n 100-133-600) was chosen in order to improve the enrichment of 
longer fragments. After the run a sequencing report was generated via the SMRT portal in order 
to assess the adapter dimer contamination, the sample loading efficiency, the obtained average 
read-length and the number of filtered sub-reads. 
DNA assembly. PacBio raw data was assembled using HGAP3 in SMRT Analysis 2.3.0 with 
default parameters. Assembled contig sequences were imported into SMRT Link 6.0, and were 
further polished using ARROW with PacBio raw data. Polishing consensus sequences were 
annotated using PROKKA (v1.0).74 
Genomic analysis. The genomic analysis of M. aeruginosa EAWAG 127a was performed using 
the online tool antiSMASH (5.0.0)6-9 and RODEO,15-16 and the data were further analyzed using 
the software Geneious (10.2.5). This Whole Genome Shotgun project has been deposited at 
DDBJ/ENA/GenBank under the accession SRLN00000000. The version described in this paper is 
version SRLN01000000. The annotation of the genes was partially achieved using the NCBI 
services. The gene cluster alignments used the following information: microviridin B gene cluster 
from M. aeruginosa NIES 843, accession number AM943877.1,44 anabaenopeptin gene cluster 
from Planktothrix agardhii NIVA-CYA 126/8, accession number EF672686.1,63 aeruginosin gene 
cluster from M. aeruginosa PCC 7806, accession number AM778955.168,69 and piricyclamide gene 
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